Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis
INTRODUCTION: Drug-free remission (DFR) and its maintenance have been defined as the most desirable outcome for rheumatoid arthritis (RA) patients. DFR is linked to resolution of arthritis-related symptoms and restoration of normal functioning. However, there is currently no consensus if an optimal strategy, upon the initiation of treatment to the proper drugs withdrawal, is enough to induce it, or whether it is a predetermined condition related to patients' intrinsic characteristics.
AREAS COVERED: This review focuses on two key concepts around DFR. First, we analyze patients' intrinsic factors that may increase the chance of DFR, regardless of therapeutic choices. Second, we discuss on the evidence that it can be induced thanks to adequate, extrinsic disease management. Finally, we provide a glimpse into consequences of drugs discontinuation.
EXPERT OPINION: The early initiation of DMARD and the subsequent strict monitoring and drug adjustments are of primary importance to allow patients to achieve DFR, irrespective of initial treatment strategy. Once remission is obtained and maintained, it is possible to gradually taper and discontinue drugs with no dramatic consequences on the disease course. Among those who stop medication, ACPA-negative patients more often maintain the remission. Thus, DFR might depend on a combination of intrinsic and extrinsic factors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Expert review of clinical immunology - 19(2023), 2 vom: 17. Feb., Seite 217-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
D'Onofrio, Bernardo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.01.2023 Date Revised 10.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/1744666X.2023.2157814 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350237050 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350237050 | ||
| 003 | DE-627 | ||
| 005 | 20231226044541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1744666X.2023.2157814 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1167.xml |
| 035 | |a (DE-627)NLM350237050 | ||
| 035 | |a (NLM)36511619 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a D'Onofrio, Bernardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inducibility or predestination? Queries and concepts around drug-free remission in rheumatoid arthritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2023 | ||
| 500 | |a Date Revised 10.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Drug-free remission (DFR) and its maintenance have been defined as the most desirable outcome for rheumatoid arthritis (RA) patients. DFR is linked to resolution of arthritis-related symptoms and restoration of normal functioning. However, there is currently no consensus if an optimal strategy, upon the initiation of treatment to the proper drugs withdrawal, is enough to induce it, or whether it is a predetermined condition related to patients' intrinsic characteristics | ||
| 520 | |a AREAS COVERED: This review focuses on two key concepts around DFR. First, we analyze patients' intrinsic factors that may increase the chance of DFR, regardless of therapeutic choices. Second, we discuss on the evidence that it can be induced thanks to adequate, extrinsic disease management. Finally, we provide a glimpse into consequences of drugs discontinuation | ||
| 520 | |a EXPERT OPINION: The early initiation of DMARD and the subsequent strict monitoring and drug adjustments are of primary importance to allow patients to achieve DFR, irrespective of initial treatment strategy. Once remission is obtained and maintained, it is possible to gradually taper and discontinue drugs with no dramatic consequences on the disease course. Among those who stop medication, ACPA-negative patients more often maintain the remission. Thus, DFR might depend on a combination of intrinsic and extrinsic factors | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-citrullinated peptide antibodies | |
| 650 | 4 | |a disease-modifying anti-rheumatic drugs | |
| 650 | 4 | |a drug-free remission | |
| 650 | 4 | |a remission | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a sustained drug-free remission | |
| 650 | 4 | |a treat-to-target | |
| 650 | 4 | |a window of opportunity | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 700 | 1 | |a van der Helm-van Mil, Annette |e verfasserin |4 aut | |
| 700 | 1 | |a W J Huizinga, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a van Mulligen, Elise |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of clinical immunology |d 2005 |g 19(2023), 2 vom: 17. Feb., Seite 217-225 |w (DE-627)NLM191372153 |x 1744-8409 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:2 |g day:17 |g month:02 |g pages:217-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1744666X.2023.2157814 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 2 |b 17 |c 02 |h 217-225 | ||